Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-852-1 | CAS number: 26628-22-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- other: Handbook data
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
- Objective of study:
- toxicokinetics
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- In vivo: Sodium azide was orally administered to rats. Blood and tissue samples were obtained and analyzed for sodium azide.
In vitro: Sodium azide was incubated with homogenates of different organs. Subsequently residual sodium azide was quantified. Reaction reates were calculated. - GLP compliance:
- no
- Radiolabelling:
- not specified
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- no data
- Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Duration and frequency of treatment / exposure:
- frequency of treatment: presumably single dose
- Dose / conc.:
- 40 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- no data
- Control animals:
- not specified
- Positive control reference chemical:
- no data
- Preliminary studies:
- Previous investigation (Toxicologist 1, 21-22) reported the absence of azide in blood and lack of toxicity of the daily dose of 23 mg/kg sodium azide in drinking water for 90 or 147 days in laboratory rats.
- Details on absorption:
- Sodium azide was detected in rat plasma 5 minutes after a single oral dose of 40 mg/kg. The calculated rate of sodium azide absorption from the gastrointestinal tract after intake of 23 mg/kg/day was equivalent only to 0.0162 mg/kg/min.
- Details on distribution in tissues:
- After 24 h, no azide could be detected in either blood or peripheral tissues.
- Details on excretion:
- A small fraction of the administered dose (7.9 µg) was eliminated in rat 24h urine, but no azide was detected in expired air or feces.
- Metabolites identified:
- yes
- Details on metabolites:
- Sodium azide is mainly metabolised in the liver with nitric oxide as main metabolite. Incubation with different (unspecified) organ homogenates exhibited no azide decomposition except for liver homogenate.
Sodium azide penetrates the blood-brain barrier. Azide anions may be metabolised to nitric oxide (NO) also in the CNS. In aqueous solution (e.g. blood), it rapidly transforms into hydrazoic acid (CAS no. 7782-79-8), which may be responsible for the irritating effects attributed to sodium azide. - Conclusions:
- Based on the presented data, sodium azide showed no bioaccumulation potential.
- Executive summary:
Sodium azide was detected in rat plasma 5 minutes after a single oral dose of 40 mg/kg bw. After 24 hours, no azide could be detected in either blood or peripheral tissues. A small fraction of the administered dose (7.9 µg) was eliminated in rat 24 h urine, but no azide was detected in expired air or feces. Sodium azide is reported to be quickly absorbed from injection sites and from the respiratory tract. Sodium azide is mainly metabolized in the liver. The main metabolite in the liver is nitric oxide (CAS 10102-43-9). Sodium azide also penetrates the blood-brain barrier and may serve as a source of nitric oxide (NO) also in the CNS. In aqueous solution, it rapidly transforms into hydrazoic acid (CAS no. 7782-79-8), which may be responsible for the irritating effects attributed to sodium azide.
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: Handbook
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
- Objective of study:
- excretion
- Qualifier:
- no guideline available
- GLP compliance:
- not specified
- Radiolabelling:
- not specified
- Species:
- human
- Strain:
- not specified
- Sex:
- not specified
- Route of administration:
- other: no data
- Vehicle:
- not specified
- Duration and frequency of treatment / exposure:
- no data
- No. of animals per sex per dose / concentration:
- no data
- Control animals:
- not specified
- Details on excretion:
- half-live: 2.5h
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: 2.5h
- Metabolites identified:
- not specified
- Conclusions:
- Sodium azide is rapidely absorbed from the gastrointestinal and respiratory tracts (as hydroazoic acid vapour). Its extent of dermal absorption is unclear. Sodium azide is metabolized by the liver and excreted by the kidneys, but human absorption, distribution, metabolism and excretion kinetics data are not available, except for a half-life of about 2.5 hours calculated in a single fatal case.
- Executive summary:
Sodium azide is rapidely absorbed from the gastrointestinal and respiratory tracts (as hydroazoic acid vapour). Its extent of dermal absorption is unclear. Sodium azide is metabolized by the liver and excreted by the kidneys, but human absorption, distribution, metabolism and excretion kinetics data are not available, except for a half-life of about 2.5 hours calculated in a single fatal case.
Referenceopen allclose all
Sodium azide was detected in the plasma as early as 5 min after the oral adminstration. No azide was identified in both plasma and tissues 24 hours later. During the same period, no azide was excreted in the feces or exhaled in the air. Only 7.9 µg of azide was excreted in the urine. Rat liver was found as the organ responsible for the deactivation of azide since in the invitro study, the liver homogenate rapidely destroyed sodium azide, whereas homogenates of other tissues did not and the azide absorbed from the gastrointestinal tract was metabolized as soon as it reached the liver. At the maximum reaction rate, one mL of 20% liver homogenate metabolized 1.13 µg sodium azide per minute. A peak level of azide in plasma, 49 µg/mL was detected after a 40 mg/kg bw dose but no azide was found in the plasma with a bolus dose of 0.38 mg/kg bw. Trace amounts were detected with 0.75 mg/kg bw. This indicated that a single oral dose of 0.38 mg/kg bw does not exceed the metabolic capacity of the liver. Also, since the oral administration required less than 10 seconds for the appearance of azide in the plasma, the calculated rate of sodium azide absorption from the gastrointestinal tract after intake of 23 mg/kg/day was equivalent only to 0.0027 mg/kg/10 sec. This intake rate is well below the metabolizing capacity of the rat liver tissue, and it is therefore not suprizing that no azide was detected in the plasma and no hematological or histopathological abnormalities were observed in the experimental animals with this dose level.
Sodium azide is rapidely absorbed from the gastrointestinal and respiratory tracts (as hydroazoic acid vapour). Its extent of dermal absorption is unclear. Sodium azide is metabolized by the liver and excreted by the kidneys, but human absorption, distribution, metabolism and excretion kinetics data are not available, except for a half-life of about 2.5 hours calculated in a single fatal case (Senda T. et al., 2001. Chudoku Kenkyu 14, 339).
Description of key information
Sodium azide is rapidly absorbed following ingestion and metabolized completely in the body as exemplified by the lack of presence of the parent compound in the faeces or exhaled air. Metabolism occurs mainly in the liver with some reports of metabolism also taking place in the brain following penetration of the blood brain barrier. Metabolism leads to the formation of nitric oxide as the main metabolite in the liver and in the brain. Sodium azide is excreted by the kidneys, but human absorption, distribution, metabolism, and excretion kinetics data are not available. There has been a report of a half-life of about 2.5 hours calculated in a single fatal case in human.
The main metabolite in the liver is nitric oxide (CAS 10102-43-9). Sodium azide also penetrates the blood-brain barrier and may serve as a source of nitric oxide (NO) also in the CNS. In aqueous solution, it rapidly transforms into hydrazoic acid (CAS no. 7782-79-8), which may be responsible for the irritating effects attributed to sodium azide.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.